<DOC>
	<DOC>NCT02601560</DOC>
	<brief_summary>A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of MEDI6012 in Subjects with Stable Coronary Artery Disease</brief_summary>
	<brief_title>Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics, of MEDI6012 in Subjects With Stable Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Men and women 40 75 years old History of Stable CAD Currently receiving statin as standard of care Severe angina pectoris symptoms Highrisk coronary or carotid artery disease that will likely require surgical or percutaneous intervention during the study period Hospitalization for heart failure within 12 months prior to screening Uncontrolled Hypertension Within 6 months prior to screening, a history of ACS or hospitalization for heart failure Clinically significant abnormalities in rhythm, conduction or morphology of ECG Subjects with transplanted heart, left ventricular assist device, implanted pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy Untreated lifethreatening ventricular arrhythmias History, within 12 months prior to screening, of myocarditis or restrictive pericarditis, or hemodynamically significant valvular hear disease or aortic disease Undergone major surgery with in 3 months prior to screening or has planned major surgery during the study period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>CAD</keyword>
</DOC>